Yohann Loriot, MD, PhD, Gustave Roussy Cancer Institute, and Vadim Koshkin, MD, University of California, San Francisco, summarize the latest data presented on cohort 1 of the THOR study, which compared erdafitinib and chemotherapy in patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor alterations.